Invesaro

Stocks Comparison

Gilead Sciences vs Neurocrine Biosciences: revenue, profit, margins and growth compared

Gilead Sciences brought in $29.4B of revenue in fiscal 2025, Neurocrine Biosciences $2.9B in fiscal 2025. Revenue changed by +2.4% at Gilead Sciences and +21.4% at Neurocrine Biosciences on the year before, so Neurocrine Biosciences grew faster. Gilead Sciences kept 28.9% of its revenue as net profit, Neurocrine Biosciences 16.7%. Free cash flow was $9.5B at Gilead Sciences and $748.7M at Neurocrine Biosciences.

Open the GILD pageOpen the NBIX page

Side by side, latest fiscal year

GILDNBIX
Fiscal year endedFY2025 (December 31, 2025)FY2025 (December 31, 2025)
Revenue$29.4B$2.9B
Revenue growth+2.4%+21.4%
Net income$8.5B$478.6M
Net margin28.9%16.7%
Free cash flow$9.5B$748.7M
Free cash flow margin32.1%26.2%
Earnings per share (diluted)$6.78$4.67
Cash$7.6B$713M
Debt$24.9Bn/a
Price to earnings22.329.6
Market value$187.1B$14.1B
Dividend yield2.09%n/a
Rank by revenue in sector#22 of 523 · Health care#88 of 523 · Health care

Over the years

Revenue
GILD FY2018: $22.1BGILD FY2019: $22.4BGILD FY2020: $24.7BGILD FY2021: $27.3BGILD FY2022: $27.3BGILD FY2023: $27.1BGILD FY2024: $28.8BGILD FY2025: $29.4BNBIX FY2018: $451.2MNBIX FY2019: $788.1MNBIX FY2020: $1BNBIX FY2021: $1.1BNBIX FY2022: $1.5BNBIX FY2023: $1.9BNBIX FY2024: $2.4BNBIX FY2025: $2.9BFY18FY19FY20FY21FY22FY23FY24FY25
GILD $29.4BNBIX $2.9B
Net income
GILD FY2018: $5.5BGILD FY2019: $5.4BGILD FY2020: $123MGILD FY2021: $6.2BGILD FY2022: $4.6BGILD FY2023: $5.7BGILD FY2024: $480MGILD FY2025: $8.5BNBIX FY2018: $21.1MNBIX FY2019: $37MNBIX FY2020: $407.3MNBIX FY2021: $89.6MNBIX FY2022: $154.5MNBIX FY2023: $249.7MNBIX FY2024: $341.3MNBIX FY2025: $478.6MFY18FY19FY20FY21FY22FY23FY24FY25
GILD $8.5BNBIX $478.6M
Net margin
GILD FY2018: 24.7%GILD FY2019: 24.0%GILD FY2020: 0.5%GILD FY2021: 22.8%GILD FY2022: 16.8%GILD FY2023: 20.9%GILD FY2024: 1.7%GILD FY2025: 28.9%NBIX FY2018: 4.7%NBIX FY2019: 4.7%NBIX FY2020: 38.9%NBIX FY2021: 7.9%NBIX FY2022: 10.4%NBIX FY2023: 13.2%NBIX FY2024: 14.5%NBIX FY2025: 16.7%FY18FY19FY20FY21FY22FY23FY24FY25
GILD 28.9%NBIX 16.7%
Revenue growth
GILD FY2019: +1.5%GILD FY2020: +10.0%GILD FY2021: +10.6%GILD FY2022: -0.1%GILD FY2023: -0.6%GILD FY2024: +6.0%GILD FY2025: +2.4%NBIX FY2019: +74.7%NBIX FY2020: +32.7%NBIX FY2021: +8.4%NBIX FY2022: +31.3%NBIX FY2023: +26.8%NBIX FY2024: +24.8%NBIX FY2025: +21.4%FY19FY20FY21FY22FY23FY24FY25
GILD +2.4%NBIX +21.4%
Free cash flow
GILD FY2018: $7.5BGILD FY2019: $8.3BGILD FY2020: $7.5BGILD FY2021: $10.8BGILD FY2022: $8.3BGILD FY2023: $7.4BGILD FY2024: $10.3BGILD FY2025: $9.5BNBIX FY2018: $76.6MNBIX FY2019: $132.3MNBIX FY2020: $217.6MNBIX FY2021: $233.1MNBIX FY2022: $322.9MNBIX FY2023: $361.6MNBIX FY2024: $557.2MNBIX FY2025: $748.7MFY18FY19FY20FY21FY22FY23FY24FY25
GILD $9.5BNBIX $748.7M

Fiscal years as each company reports them; the two may end in different months.

Questions about Gilead Sciences and Neurocrine Biosciences

Which is bigger by revenue, Gilead Sciences or Neurocrine Biosciences?

Gilead Sciences is bigger by revenue: $29.4B in fiscal 2025, against $2.9B for Neurocrine Biosciences in fiscal 2025.

Which keeps more of its revenue as profit, Gilead Sciences or Neurocrine Biosciences?

Gilead Sciences had a net margin of 28.9% in fiscal 2025; Neurocrine Biosciences had 16.7% in fiscal 2025.

Which grew revenue faster, Gilead Sciences or Neurocrine Biosciences?

In their latest fiscal years revenue changed by +2.4% at Gilead Sciences and +21.4% at Neurocrine Biosciences.

Where do these numbers come from?

From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.

More comparisons

AMGN vs GILD
BIIB vs GILD
EXEL vs GILD
AMGN vs NBIX
BIIB vs NBIX
EXEL vs NBIX

Compare more companies